[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE399026T1 - Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern - Google Patents

Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern

Info

Publication number
ATE399026T1
ATE399026T1 AT04811351T AT04811351T ATE399026T1 AT E399026 T1 ATE399026 T1 AT E399026T1 AT 04811351 T AT04811351 T AT 04811351T AT 04811351 T AT04811351 T AT 04811351T AT E399026 T1 ATE399026 T1 AT E399026T1
Authority
AT
Austria
Prior art keywords
type calcium
blockers
canal
compositions containing
cholinesterase inhibitors
Prior art date
Application number
AT04811351T
Other languages
English (en)
Inventor
Crista Murphy
Gregory Rose
Axel Unterbeck
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Application granted granted Critical
Publication of ATE399026T1 publication Critical patent/ATE399026T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AT04811351T 2003-11-21 2004-11-19 Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern ATE399026T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52366403P 2003-11-21 2003-11-21
US60811604P 2004-09-09 2004-09-09

Publications (1)

Publication Number Publication Date
ATE399026T1 true ATE399026T1 (de) 2008-07-15

Family

ID=34636482

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811351T ATE399026T1 (de) 2003-11-21 2004-11-19 Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern

Country Status (9)

Country Link
US (4) US20080026081A1 (de)
EP (3) EP1684755A1 (de)
JP (2) JP2007512339A (de)
AT (1) ATE399026T1 (de)
AU (2) AU2004292967A1 (de)
CA (2) CA2546366A1 (de)
DE (1) DE602004014635D1 (de)
ES (1) ES2309594T3 (de)
WO (2) WO2005051426A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1649132B1 (de) 2003-07-09 2007-01-10 Shell Internationale Researchmaatschappij B.V. Werkzeug zum ausheben eines objekts
RU2006117331A (ru) 2003-10-21 2007-12-10 Шелл Интернэшнл Рисерч Маатсхаппий Б.В. (NL) Узел сопла и способ бурения отверстия в объекте
ATE374304T1 (de) 2003-10-29 2007-10-15 Shell Int Research Fluidstrahlbohrwerkzeug
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
CN101247795B (zh) 2005-04-06 2012-02-01 埃德莫斯药品有限公司 用于治疗与中枢神经系统（cns）相关疾病的方法和组合物
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
WO2008109343A1 (en) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009051922A1 (en) * 2007-10-15 2009-04-23 Memory Pharmaceuticals Corporation Methods of treating alzheimer's disease with (+) - isopropyl 2-methoxyethyl 4-(2-chloro-3- cyano-phenyl) -1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate and a cholinesterase inhibitor
JP2011518783A (ja) * 2008-04-09 2011-06-30 コンサート ファーマシューティカルズ インコーポレイテッド ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
JP5616345B2 (ja) * 2008-09-18 2014-10-29 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２のベンゾキノリン阻害剤
US20100143505A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Indanone inhibitors of acetylcholinesterase
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
WO2010132671A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
CA2799162A1 (en) * 2010-05-13 2011-11-17 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
BR112015005894B1 (pt) 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CA2978006C (en) 2015-03-06 2024-06-25 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
WO2017117586A1 (en) * 2015-12-31 2017-07-06 Bach Pharma, Inc. Compositions and nethods for treating brain dysfunction
EP3436021A4 (de) * 2016-03-29 2019-11-06 RespireRx Pharmaceuticals Inc. Zusammensetzungen und verfahren zur behandlung von aufmerksamkeitsdefizitstörungen
AU2017281789B2 (en) 2016-06-23 2023-04-13 Corium, LLC. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
KR102545643B1 (ko) 2016-07-27 2023-06-21 코리움, 엘엘씨 도네페질 경피 전달 시스템
CA3031944A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
SG11201900712SA (en) 2016-07-27 2019-02-27 Corium Int Inc Memantine transdermal delivery systems
AU2018307792B2 (en) 2017-07-26 2024-08-08 Corium, LLC. Transdermal delivery system with a microporous membrane having solvent-filled pores
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
WO2024136579A1 (ko) * 2022-12-22 2024-06-27 서울대학교산학협력단 도파민 생성 억제제 또는 도파민 수용체 길항제를 포함하는 인지기능 장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE03192B1 (et) * 1993-12-10 1999-06-15 Bayer Aktiengesellschaft Isopropüül-(2-metoksüetüül)-4-(2-kloro-3-tsüanofenüül)-1,4-dihüdro-2,6-dimetüülpüri diin-3,5-dikarboksülaat, selle enantiomeerid ja vaheühend, meetodid nimetatud ühendite valmistamiseks ja kasutamine
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
EP0985667A4 (de) * 1997-04-25 2000-03-22 Ajinomoto Kk Neue dihydropyridin-derivate
US6979698B1 (en) * 1997-08-11 2005-12-27 Targacept, Inc. Method of treating cognitive deficits in learning and memory
KR20010033442A (ko) * 1997-12-22 2001-04-25 에가시라 구니오 신규 디하이드로피리딘 유도체
US6440967B1 (en) * 1998-11-12 2002-08-27 Merck & Co., Inc. Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors

Also Published As

Publication number Publication date
AU2004292966A1 (en) 2005-06-09
CA2546395A1 (en) 2005-06-09
US20090156639A1 (en) 2009-06-18
WO2005051389A1 (en) 2005-06-09
ES2309594T3 (es) 2008-12-16
DE602004014635D1 (de) 2008-08-07
US20080026081A1 (en) 2008-01-31
WO2005051426A1 (en) 2005-06-09
EP1684806A1 (de) 2006-08-02
JP2007512338A (ja) 2007-05-17
JP2007512339A (ja) 2007-05-17
EP1684806B1 (de) 2008-06-25
US20050153953A1 (en) 2005-07-14
AU2004292967A1 (en) 2005-06-09
CA2546366A1 (en) 2005-06-09
EP1684755A1 (de) 2006-08-02
EP1952824A1 (de) 2008-08-06
AU2004292967A2 (en) 2005-06-09
US20090069361A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
ATE399026T1 (de) Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
IS2520B (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
DE60324544D1 (de) Muskarin antagonisten
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
DK1596880T3 (da) Fremgangsmåder og sammensætninger til undertrykkelse af fibrocytdifferentiering
IS7718A (is) Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar
IS6950A (is) Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
HK1085511A1 (en) Complement inhibitors from ticks
DE50115252D1 (de) Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion
DK1365762T3 (da) Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE482200T1 (de) Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
CY1117051T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης
EA200600535A1 (ru) Полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
MXPA05008126A (es) Inhibidores de girasa y uso de los mismos.
HK1083451A1 (en) N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
DE60217532T8 (de) Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
ATE443044T1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
NO20070878L (no) Dimere piperidinderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties